Diabetes Research and Clinical Practice
Volume 76, Issue 2 , Pages 177-186 , May 2007

Novel roles of the IGF–IGFBP axis in etiopathophysiology of diabetic nephropathy

  • Tetyana L. Vasylyeva

      Affiliations

    • Department of Pediatrics, Texas Tech University Health Science Center, Amarillo, TX, United States
    • ,
  • Robert J. Ferry Jr.

      Affiliations

    • Division of Pediatric Endocrinology and Diabetes, Departments of Pediatrics and Cellular & Structural Biology, The University of Texas Health Science Center, San Antonio, TX, United States
    • Headquarters and Headquarters Support Company, 111th Area Support Medical Battalion, Texas Army National Guard, San Antonio, TX, United States
    • Corresponding Author InformationCorresponding author at: Division of Pediatric Endocrinology and Diabetes, Room 540F-4, MSC 7806, UTHSCSA, 7703 Floyd Curl Drive, San Antonio, TX 78229-3900, United States. Tel.: +1 210 567 5283; fax: +1 210 567 0492.

Received 21 May 2006 ,Accepted 4 September 2006.

References 

  1. Chiarelli F, Trotta D, Verrotti A, Mohn A. Kidney involvement and disease in patients with diabetes. Panminerva Med. 2003;45:23–41
  2. Campbell F. Microalbuminuria and nephropathy in insulin-dependent diabetes mellitus. Arch. Dis. Child. 1995;73:4–7
  3. Quattrin T, Waz WR, Duffy L, Sheldon MW, Campos SP, Albini CH, et al. Microalbuminuria in an adolescent cohort with insulin-dependent diabetes mellitus. Clin. Pediatr. 1995;34:12–17
  4. Mauer S, Steffes M, Brown D. The kidney in diabetes. Am. J. Med. 1981;70:603–612
  5. Mauer S, Steffes M, Ellis E, Sutherland D, Brown DM, Goetz FC. Structural–functional relationships in diabetic nephropathy. J. Clin. Invest. 1984;74:1143–1155
  6. Osterby R. A quantitative electron microscopic study of mesangial regions in glomeruli from patients with short-term juvenile diabetes mellitus. Lab. Invest. 1973;29:99–110
  7. Steffes MW, Osterby R, Chavers B, Mayer SM. Mesangial expansion as a central mechanism for loss of kidney function in diabetic patients. Diabetes. 1989;38:1077–1081
  8. Karl M, Potier M, Schulman I, Rivera A, Werner H, Fornoni A, et al. Autocrine activation of the local insulin-like growth factor I system is up-regulated by estrogen receptor (ER)-independent estrogen actions and accounts for decreased ER expression in type 2 diabetic mesangial cells. Endocrinology. 2005;146:889–900
  9. Flyvbjerg A. Putative pathophysiological role of growth factors and cytokines in experimental diabetic kidney disease. Diabetologia. 2000;43:1205–1223
  10. Flyvbjerg A, Frystyk J, Osterby R, Orskov H. Kidney IGF-I and renal hypertrophy in GH-deficient diabetic dwarf rats. Am. J. Physiol. 1992;262:E956–E962
  11. Flyvbjerg A, Khatir D, Jensen L, Dagnæs-Hansen F, Gronbaek H, Rasch R. The involvement of growth hormone (GH), insulin-like growth factors (IGFs) and vascular endothelial growth factor (VEGF) in diabetic kidney disease. Curr. Pharm. Des. 2004;10:3385–3394
  12. Ferry RJ, Cohen P. The insulin-like growth factor axis in pediatrics. Clin. Pediatr. Endocrinol. 1999;8:1–10
  13. Firth S, Baxter R. Cellular actions of the insulin-like growth factor binding proteins. Endocr. Rev. 2002;23:824–854
  14. Raz I, Wexler I, Weiss O, Flyvbjerg A, Segev Y, Rauchwerger A, et al. Role of insulin and the IGF system in renal hypertrophy in diabetic Psammomys obesus (sand rat). Nephrol. Dial. Transplant. 2003;18:1293–1298
  15. Gambaro G, Baggio B. Growth factors and the kidney in diabetes mellitus. Crit. Rev. Clin. Lab. Sci. 1998;35:117–151
  16. Garay-Sevilla M, Nava L, Malacara J, Nava LE, Wrobel-Zasada K, Castro-Rivas A, et al. Advanced glycosylation end products (AGEs), insulin-like growth factor-1 (IGF-1) and IGF-binding protein-3 (IGFBP-3) in patients with type 2 diabetes mellitus. Diab. Metab. Res. Rev. 2000;16:106–113
  17. Fornoni A, Li H, Foschi A, Stiker LJ. Hepatocyte growth factor, but not insulin-like growth factor I, protects podocytes against cyclosporin A-induced apoptosis. Am. J. Pathol. 2001;158:275–280
  18. Abrass C, Raugi G, Gabourel L, Lovet DH. Insulin and insulin-like growth factor I binding to cultured rat glomerular mesangial cells. Endocrinology. 1988;123:2432–2439
  19. Sanaka T. Nutritional effect of dialysis therapy. Artif. Organs. 2003;27:224–226
  20. Abrass C, Berfield A, Andress D. Heparin binding domain of insulin-like growth factor binding protein-5 stimulates mesangial cell migration. Am. J. Physiol. 1997;273:F899–F906
  21. Berfield A, Andress D, Abrass C. IGF-1-induced lipid accumulation impairs mesangial cell migration and contractile function. Kidney Int. 2002;62:1229–1237
  22. Phillips S, DeRubertis F, Craven P. Regulation of the laminin C1 promoter in cultured mesangial cells. Diabetes. 1999;48:2083–2089
  23. Trachtman H, Koss I, Bogart M, Abramowitz J, Futterweit S, Franki N, et al. High glucose enhances growth factor-stimulated nitric oxide production by cultured rat mesangial cells. Res. Commun. Mol. Pathol. Pharmacol. 1998;100:213–225
  24. Vasylyeva TL, Chen X, Ferry RJ. Insulin-like growth factor binding protein-3 mediates cytokine-induced mesengial cell apoptosis. Growth Horm. IGF Res. 2005;15(3):207–214
  25. Berfield A, Spicer D, Abrass C. Insulin-like growth factor I (IGF-I) induces unique effects in the cytoskeleton of cultured rat glomerular mesangial cells. J. Histochem. Cytochem. 1997;45:583–593
  26. Horney M, Shirley D, Kurtz D, Rosenzweig SA. Elevated glucose increases mesangial cell sensitivity to insulin-like growth factor I. Am. J. Physiol. 1998;274:F1045–F1053
  27. White K, Bilous R, Marshall S, El Nahas M, Remuzzi G, Piras G, et al. Podocyte number in normotensive type 1 diabetic patients with albuminuria. Diabetes. 2002;51:3083–3089
  28. Sukegawa I, Hizuka N, Takano K, Asakawa K, Shizume K. Characterization of insulin-like growth factor I receptors on Madin–Darby canine kidney (MDCK) cell line. Endocrinol. Jpn. 1987;34:339–346
  29. Li W, Fawcett J, Widmer HR, Fielder PJ, Rabkin R, Keller G-A. Nuclear transport of insulin-like growth factor-I and insulin-like growth factor binding protein-3 in opossum kidney cells. Endocrinology. 1997;138:1763–1766
  30. Senthil D, Choudhury G, Abboud H, Sonenberg N, Kasinath BS. Regulation of protein synthesis by IGF-I in proximal tubular epithelial cells. Am. J. Physiol. Renal Physiol. 2002;283:F1226–F1236
  31. Shalamanova L, Kubler B, Scharf JG, Braulke T. MDCK cells secrete neutral proteases cleaving insulin-like growth factor-binding protein-2 to -6. Am. J. Physiol. Endocrinol. Metab. 2001;281:E1221–E1229
  32. Tsilibary E. Microvascular basement membranes in diabetes mellitus. J. Pathol. 2003;200:537–546
  33. Makino H, Sugimoto H, Shikata K. Diabetic nephropathy—recent advances in its mechanism and treatment. Nippon Rinsho. 1999;57:590–600
  34. Flyvbjerg A. Potential use of growth hormone receptor antagonist in the treatment of diabetic kidney disease. Growth Horm. IGF Res. 2001;11:S115–S119
  35. Doi T, Striker LJ, Gibson CC, Agodoa LY, Brinster RL, Striker GE. Glomerular lesions in mice transgenic for growth hormone and insulinlike growth factor-I. I. Relationship between increased glomerular size and mesangial sclerosis. Am. J. Pathol. 1990;137:541–552
  36. Cingel-Ristic V, Schrijvers BF, van Vliet AK, Rash R, Han V, Drop SL, et al. Kidney growth in normal and diabetic mice is not affected by human insulin-like growth factor binding protein-1 administration. Exp. Biol. Med. 2005;230:135–143
  37. Doublier S, Seurin D, Fouqueray B, Verpont C, Callard P, Striker LJ, et al. Glomerulosclerosis in mice transgenic for human insulin-like growth factor-binding protein-1. Kidney Int. 2000;57:2299–2307
  38. Bortz J, Rotwein P, DeVol D, Bechtel PJ, Hansen VA, Hammerman MP. Focal expression of insulin-like growth factor I in rat kidney collecting duct. J. Cell Biol. 1988;107:811–819
  39. Werner H, Shen-Orr Z, Stannard B, Burguera B, Roberts CT, LeRoith D. Experimental diabetes increases insulin-like growth factor I and II receptor concentration and gene expression in kidney. Diabetes. 1990;39:1490–1497
  40. Landau D, Israel E, Rivkis I, Kachko L, Schrijvers BF, Flyvbjerg A, et al. The effect of growth hormone on the development of diabetic kidney disease in rats. Nephrol. Dial. Transplant. 2003;18:694–702
  41. Wang S, Lapage J, Hirschberg R. Glomerular ultrafiltration of IGF-I may contribute to increased renal sodium retention in diabetic nephropathy. J. Lab. Clin. Med. 1999;134:154–160
  42. Phillip M, Werner H, Palese T, Kowarski AA, Stannard B, Bach LA, et al. Differential accumulation of insulin-like growth factor-I in kidneys of pre- and postpubertal streptozotocin-diabetic rats. J. Mol. Endocrinol. 1994;12:215–224
  43. Miyatake N, Shikata K, Wada J, Sugimoto H, Takahashi S-I, Makino H. Differential distribution of insulin-like growth factor-1 and insulin-like growth factor binding proteins in experimental diabetic rat kidney. Nephron. 1999;81:317–323
  44. Park I, Kiyomoto H, Alvarez F, Xu YC, Abboud HE, Abboud SL. Preferential expression of insulin-like growth factor binding proteins-1, -3, and -5 during early diabetic renal hypertrophy in rats. Am. J. Kidney Dis. 1998;32:1000–1010
  45. Spagnoli A, Chiarelli F, Vorwerk P, Boscherini B, Rosenfeld RG. Evaluation of the components of insulin-like growth factor (IGF)-IGF binding protein (IGFBP) system in adolescents with type 1 diabetes and persistent microalbuminuria: relationship with increased urinary excretion of IGFBP-3 18kD N-terminal fragment. Clin Endocrinol. 1999;51:587–596
  46. Verrotti A, Cieri F, Petitti MT, Morgese G, Chiarelli F. Growth hormone and IGF-I in diabetic children with and without microalbuminuria. Diab. Nutr. Metab. 1999;12:271–276
  47. Shinada M, Akdeniz A, Panagiotopoulos S, Jerums G, Bach LA. Proteolysis of insulin-like growth factor-binding protein-3 is increased in urine from patients with diabetic nephropathy. J. Clin. Endocrinol. Metab. 2000;85:1163–1169
  48. Jehle PM, Jehle DR, Mohan S, Bochm BO. Serum levels of insulin-like growth factor system components and relationship to bone metabolism in Type 1 and Type 2 diabetes mellitus patients. J. Endocrinol. 1998;159:297–306
  49. Gambaro G, Baggio B. Growth factors and the kidney in diabetes mellitus. Crit. Rev. Clin. Lab. Sci. 1998;35:117–151
  50. Bambola O, Kaskel F. Growth hormone therapy in chronic kidney disease. Growth Genet. Horm. 2005;12:7–14
  51. Landau D, Segev Y, Afargan M. A novel somatostatin analogue prevents early renal complications in the nonobese diabetic mouse. Kidney Int. 2001;60:505–512
  52. Segev Y, Landau D, Rasch R, Flyvbjerg A, Phillip M. Growth hormone receptor antagonism prevents early renal changes in nonobese diabetic mice. J. Am. Soc. Nephrol. 1999;10:2374–2381
  53. Bach LA. IGF-I and IGF binding proteins in diabetes-related kidney growth. Growth Regul. 1992;2:30–39
  54. Orskov H. Somatostatin, growth hormone, insulin-like growth factor-1, and diabetes: friends or foes?. Metabolism. 1996;45:91–95
  55. Chen NY, Chen WY, Bellush L, Yang CW, Striker LJ, Striker GE, et al. Effects of streptozotocin treatment in growth hormone (GH) and GH antagonist transgenic mice. Endocrinology. 1995;136:660–667
  56. Bach L, Dean R, Youssef S, Cooper ME. Aminoguanidine ameliorates changes in the IGF system in experimental diabetic nephropathy. Nephrol. Dial. Transplant. 2000;15:347–354
  57. P. Pennisi, O. Gavrilova, J. Setser-Portas, W. Jou, S. Santopietro, D. Clemmons, Recombinant Human Insulin-Like Growth Factor-I (rhIGF-1) treatment inhibits gluconeogenesis in a transgenic mouse model of type 2 Diabetes Mellitus (DM), Endocrinology, 2006 (epub ahead of print).
  58. Segev Y, Eshet R, Rivkis I, Hayat C, Kachko L, Phillip M, et al. Comparison between somatostatin analogues and ACE inhibitor in the NOD mouse model of diabetic kidney disease. Nephrol. Dial. Transplant. 2004;19:3021–3028
  59. Alric Pecher C, Cellier E, Schanstra JP, Poirier B, Chevalier J, et al. Inhibition of IGF-I-induced Erk 1 and 2 activation and mitogenesis in mesangial cells by bradykinin. Kidney Int. 2002;62:412–421
  60. Chen X, Ferry RJ. Novel actions of IGFBP-3 on intracellular signaling pathways in insulin-secreting cells. Growth Horm. IGF Res. 2006;16:41–48(Erratum in Growth Horm. IGF Res. 16 (2006) 276)
  61. Franklin SL, Ferry RJ, Cohen P. Rapid insulin-like growth factor (IGF)-independent effects of IGF binding protein-3 on endothelial cell survival. J. Clin. Endocrinol. Metab. 2003;88:900–907

PII: S0168-8227(06)00395-0

doi: 10.1016/j.diabres.2006.09.012

Diabetes Research and Clinical Practice
Volume 76, Issue 2 , Pages 177-186 , May 2007

Article Tools

* Image Usage & Resolution